Working together with Primary Care to improve Kidney Outcomes

in People with Diabetes

Invokana^®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC.

Prescribing information can be found next to the watch the webinar buttons.
These recordings are intended for UK Healthcare Professionals only. Please ensure members of the public can't see or hear the content

Working together with Primary Care to improve Kidney Outcomes in People with Diabetes

Description:
This video is part of The Many Faces of Diabetes webinar titled “Glycaemic control and renal and cardiovascular outcomes in type 2 diabetes”. Dr Janaka Karalliedde’s presentation explores how primary and secondary care can work together to provide better outcomes for people with type 2 diabetes.
Presented at The Many Faces of Diabetes national webinar on 13th July 2023.
Duration 17 minutes

Useful Resources

Dr Karalliedde is a Clinical Reader in Diabetes and Cardiovascular Disease at the School of Cardiovascular Medicine & Sciences at King’s College London and Consultant Physician in Diabetes and Endocrinology and Internal Medicine at Guy’s and St Thomas’ NHS Foundation Trust, London. He graduated with a distinction in medicine from the University of London and was awarded a UK Medical Research Council Clinical Research Training Fellowship and PhD by the University of London for research on the pathophysiology and treatment of cardiovascular disease and renal disease in diabetes. His research training took place in Professor Giancarlo Viberti’s Research Unit at Guy’s and St Thomas’ NHS Foundation Trust, London.

PP-ENDO-UK-141 September 2023